{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:53:58Z","timestamp":1791327238987,"version":"4.3.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T00:00:00Z","timestamp":1704844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100017559","name":"Recordati Rare Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017559","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40268-023-00449-z","type":"journal-article","created":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T05:02:05Z","timestamp":1704862925000},"page":"69-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Experience of Carglumic Acid for Methylmalonic and Propionic Acidurias: An Interim Analysis of the Multicentre Observational PROTECT Study"],"prefix":"10.1007","volume":"24","clinical-trial-number":[{"clinical-trial-number":"nct04176523","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Sufin","family":"Yap","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Lamireau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Feillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angeles","family":"Ruiz Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Davison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine","family":"Tangeraas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,10]]},"reference":[{"issue":"4","key":"449_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s12291-011-0134-2","volume":"26","author":"K Vaidyanathan","year":"2011","unstructured":"Vaidyanathan K, Narayanan MP, Vasudevan DM. Organic acidurias: an updated review. Indian J Clin Biochem. 2011;26(4):319\u201325. https:\/\/doi.org\/10.1007\/s12291-011-0134-2.","journal-title":"Indian J Clin Biochem"},{"issue":"6","key":"449_CR2","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1172\/JCI109614","volume":"64","author":"FX Coude","year":"1979","unstructured":"Coude FX, Sweetman L, Nyhan WL. Inhibition by propionyl-coenzyme A of N-acetylglutamate synthetase in rat liver mitochondria: a possible explanation for hyperammonemia in propionic and methylmalonic acidemia. J Clin Invest. 1979;64(6):1544\u201351. https:\/\/doi.org\/10.1172\/JCI109614.","journal-title":"J Clin Invest"},{"issue":"1","key":"449_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1542\/peds.69.1.115","volume":"69","author":"FX Coude","year":"1982","unstructured":"Coude FX, Ogier H, Grimber G, et al. Correlation between blood ammonia concentration and organic acid accumulation in isovaleric and propionic acidemia. Pediatrics. 1982;69(1):115\u20137.","journal-title":"Pediatrics"},{"issue":"1","key":"449_CR4","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1542\/peds.2010-0008","volume":"126","author":"N Ah Mew","year":"2010","unstructured":"Ah Mew N, McCarter R, Daikhin Y, Nissim I, Yudkoff M, Tuchman M. N-carbamylglutamate augments ureagenesis and reduces ammonia and glutamine in propionic acidemia. Pediatrics. 2010;126(1):e208\u201314. https:\/\/doi.org\/10.1542\/peds.2010-0008.","journal-title":"Pediatrics"},{"key":"449_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/IJGM.S10490","volume":"4","author":"M Daniotti","year":"2011","unstructured":"Daniotti M, la Marca G, Fiorini P, Filippi L. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int J Gen Med. 2011;4:21\u20138. https:\/\/doi.org\/10.2147\/IJGM.S10490.","journal-title":"Int J Gen Med."},{"issue":"6","key":"449_CR6","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00431-010-1362-9","volume":"170","author":"CS Kasapkara","year":"2011","unstructured":"Kasapkara CS, Ezgu FS, Okur I, Tumer L, Biberoglu G, Hasanoglu A. N-carbamylglutamate treatment for acute neonatal hyperammonemia in isovaleric acidemia. Eur J Pediatr. 2011;170(6):799\u2013801. https:\/\/doi.org\/10.1007\/s00431-010-1362-9.","journal-title":"Eur J Pediatr"},{"key":"449_CR7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13023-014-0130-8","volume":"9","author":"MR Baumgartner","year":"2014","unstructured":"Baumgartner MR, H\u00f6rster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130. https:\/\/doi.org\/10.1186\/s13023-014-0130-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"449_CR8","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/jimd.12370","volume":"44","author":"P Forny","year":"2021","unstructured":"Forny P, Horster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: first revision. J Inherit Metab Dis. 2021;44(3):566\u201392. https:\/\/doi.org\/10.1002\/jimd.12370.","journal-title":"J Inherit Metab Dis"},{"issue":"1\u20132","key":"449_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ymgme.2017.07.003","volume":"122","author":"N Longo","year":"2017","unstructured":"Longo N, Price LB, Gappmaier E, et al. Anaplerotic therapy in propionic acidemia. Mol Genet Metab. 2017;122(1\u20132):51\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2017.07.003.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"449_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s10545-013-9600-8","volume":"36","author":"S K\u00f6lker","year":"2013","unstructured":"K\u00f6lker S, Burgard P, Sauer SW, Okun JG. Current concepts in organic acidurias: understanding intra- and extracerebral disease manifestation. J Inherit Metab Dis. 2013;36(4):635\u201344. https:\/\/doi.org\/10.1007\/s10545-013-9600-8.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"449_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1001\/archneurol.2009.333","volume":"67","author":"FD Testai","year":"2010","unstructured":"Testai FD, Gorelick PB. Inherited metabolic disorders and stroke part 2: homocystinuria, organic acidurias, and urea cycle disorders. Arch Neurol. 2010;67(2):148\u201353. https:\/\/doi.org\/10.1001\/archneurol.2009.333.","journal-title":"Arch Neurol"},{"key":"449_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-94-009-5612-4_29","volume":"7 Suppl. 2","author":"RA Chalmers","year":"1984","unstructured":"Chalmers RA, Stacey TE, Tracey BM, et al. L-Carnitine insufficiency in disorders of organic acid metabolism: response to L-carnitine by patients with methylmalonic aciduria and 3-hydroxy-3-methylglutaric aciduria. J Inherit Metab Dis. 1984;7 Suppl. 2:109\u201310. https:\/\/doi.org\/10.1007\/978-94-009-5612-4_29.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"449_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1042\/BJ20060221","volume":"398","author":"MA Schwab","year":"2006","unstructured":"Schwab MA, Sauer SW, Okun JG, et al. Secondary mitochondrial dysfunction in propionic aciduria: a pathogenic role for endogenous mitochondrial toxins. Biochem J. 2006;398(1):107\u201312. https:\/\/doi.org\/10.1042\/BJ20060221.","journal-title":"Biochem J"},{"key":"449_CR14","volume-title":"Organic acidurias","author":"K Bartlett","year":"1984","unstructured":"Bartlett K, Ghneim HK, Stirk J, Dale G, Alberti KGMM. Pyruvate carboxylase deficiency. In: Addison GM, Chalmers RA, Divry P, Harkness RA, Pollitt RJ, editors. Organic acidurias. Dordrecht: Springer; 1984."},{"issue":"17","key":"449_CR15","doi-asserted-by":"publisher","first-page":"14674","DOI":"10.1074\/jbc.M200997200","volume":"277","author":"JG Okun","year":"2002","unstructured":"Okun JG, H\u00f6rster F, Farkas LM, et al. Neurodegeneration in methylmalonic aciduria involves inhibition of complex II and the tricarboxylic acid cycle, and synergistically acting excitotoxicity. J Biol Chem. 2002;277(17):14674\u201380. https:\/\/doi.org\/10.1074\/jbc.M200997200.","journal-title":"J Biol Chem"},{"issue":"5","key":"449_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/s41582-019-0161-9","volume":"15","author":"M Wajner","year":"2019","unstructured":"Wajner M. Neurological manifestations of organic acidurias. Nat Rev Neurol. 2019;15(5):253\u201371. https:\/\/doi.org\/10.1038\/s41582-019-0161-9.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"449_CR17","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1001\/archneur.56.9.1143","volume":"56","author":"WL Nyhan","year":"1999","unstructured":"Nyhan WL, Bay C, Beyer EW, Mazi M. Neurologic nonmetabolic presentation of propionic acidemia. Arch Neurol. 1999;56(9):1143\u20137. https:\/\/doi.org\/10.1001\/archneur.56.9.1143.","journal-title":"Arch Neurol"},{"key":"449_CR18","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/1750-1172-8-148","volume":"8","author":"M Nizon","year":"2013","unstructured":"Nizon M, Ottolenghi C, Valayannopoulos V, et al. Long-term neurological outcome of a cohort of 80 patients with classical organic acidurias. Orphanet J Rare Dis. 2013;8:148. https:\/\/doi.org\/10.1186\/1750-1172-8-148.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"449_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1177\/088307389501000107","volume":"10","author":"RL Hamilton","year":"1995","unstructured":"Hamilton RL, Haas RH, Nyhan WL, Powell HC, Grafe MR. Neuropathology of propionic acidemia: a report of two patients with basal ganglia lesions. J Child Neurol. 1995;10(1):25\u201330. https:\/\/doi.org\/10.1177\/088307389501000107.","journal-title":"J Child Neurol"},{"issue":"2\u20133","key":"449_CR20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10545-006-0278-z","volume":"29","author":"C Dionisi-Vici","year":"2006","unstructured":"Dionisi-Vici C, Deodato F, R\u00f6schinger W, Rhead W, Wilcken B. \u201cClassical\u201d organic acidurias, propionic aciduria, methylmalonic aciduria and isovaleric aciduria: long-term outcome and effects of expanded newborn screening using tandem mass spectrometry. J Inherit Metab Dis. 2006;29(2\u20133):383\u20139. https:\/\/doi.org\/10.1007\/s10545-006-0278-z.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"449_CR21","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ymgme.2009.07.010","volume":"98","author":"M Yudkoff","year":"2009","unstructured":"Yudkoff M, Ah Mew N, Payan I, et al. Effects of a single dose of N-carbamylglutamate on the rate of ureagenesis. Mol Genet Metab. 2009;98(4):325\u201330. https:\/\/doi.org\/10.1016\/j.ymgme.2009.07.010.","journal-title":"Mol Genet Metab"},{"issue":"12","key":"449_CR22","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1007\/s00431-013-2205-2","volume":"173","author":"A Van Leynseele","year":"2014","unstructured":"Van Leynseele A, Jansen A, Goyens P, et al. Early treatment of a child with NAGS deficiency using N-carbamyl glutamate results in a normal neurological outcome. Eur J Pediatr. 2014;173(12):1635\u20138. https:\/\/doi.org\/10.1007\/s00431-013-2205-2.","journal-title":"Eur J Pediatr"},{"key":"449_CR23","volume-title":"Hyperammonemia","author":"R Ali","year":"2022","unstructured":"Ali R, Nagalli S. Hyperammonemia. StatPearls. Treasure Island: StatPearls Publishing; 2022."},{"key":"449_CR24","unstructured":"European Medicines Agency (EMA). Carbaglu 200 mg dispersible tablets: summary of product characteristics. 2003. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/carbaglu-epar-product-information_en.pdf. Accessed 23 Feb 2021."},{"key":"449_CR25","unstructured":"European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). Carbaglu: summary of opinion (post authorisation). EMA\/CHMP\/306613\/2011. 2011. https:\/\/www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-carbaglu_en.pdf. Accessed 11 Mar 2021."},{"issue":"1","key":"449_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13023-018-0840-4","volume":"13","author":"A Chakrapani","year":"2018","unstructured":"Chakrapani A, Valayannopoulos V, Garc\u00eda Segarra N, et al. Effect of carglumic acid with or without ammonia scavengers on hyperammonaemia in acute decompensation episodes of organic acidurias. Orphanet J Rare Dis. 2018;13(1):97. https:\/\/doi.org\/10.1186\/s13023-018-0840-4.","journal-title":"Orphanet J Rare Dis"},{"key":"449_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-016-0406-2","volume":"11","author":"V Valayannopoulos","year":"2016","unstructured":"Valayannopoulos V, Baruteau J, Delgado MB, et al. Carglumic acid enhances rapid ammonia detoxification in classical organic acidurias with a favourable risk-benefit profile: a retrospective observational study. Orphanet J Rare Dis. 2016;11:32. https:\/\/doi.org\/10.1186\/s13023-016-0406-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"449_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13023-021-02032-8","volume":"16","author":"M Alfadhel","year":"2021","unstructured":"Alfadhel M, Nashabat M, Saleh M, et al. Long-term effectiveness of carglumic acid in patients with propionic acidemia (PA) and methylmalonic acidemia (MMA): a randomized clinical trial. Orphanet J Rare Dis. 2021;16(1):422. https:\/\/doi.org\/10.1186\/s13023-021-02032-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"449_CR29","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13256-018-1631-1","volume":"12","author":"A Tummolo","year":"2018","unstructured":"Tummolo A, Melpignano L, Carella A, et al. Long-term continuous N-carbamylglutamate treatment in frequently decompensated propionic acidemia: a case report. J Med Case Rep. 2018;12(1):103. https:\/\/doi.org\/10.1186\/s13256-018-1631-1.","journal-title":"J Med Case Rep"},{"key":"449_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4709548","author":"J Kido","year":"2020","unstructured":"Kido J, Matsumoto S, Nakamura K. Carglumic acid contributes to a favorable clinical course in a case of severe propionic acidemia. Case Rep Pediatr. 2020. https:\/\/doi.org\/10.1155\/2020\/4709548.","journal-title":"Case Rep Pediatr."},{"key":"449_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ymgmr.2016.06.007","volume":"8","author":"A Burlina","year":"2016","unstructured":"Burlina A, Cazzorla C, Zanonato E, Viggiano E, Fasan I, Polo G. Clinical experience with N-carbamylglutamate in a single-centre cohort of patients with propionic and methylmalonic aciduria. Mol Genet Metab Rep. 2016;8:34\u201340. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.06.007.","journal-title":"Mol Genet Metab Rep."},{"key":"449_CR32","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.ymgmr.2021.100715","volume":"26","author":"E Kiykim","year":"2021","unstructured":"Kiykim E, Oguz O, Duman C, Zubarioglu T, Cansever MS, Zeybek ACA. Long-term N-carbamylglutamate treatment of hyperammonemia in patients with classic organic acidemias. Mol Genet Metab Rep. 2021;26:100715. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100715.","journal-title":"Mol Genet Metab Rep."},{"issue":"3","key":"449_CR33","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000255168","volume":"97","author":"L Filippi","year":"2010","unstructured":"Filippi L, Gozzini E, Fiorini P, Malvagia S, la Marca G, Donati MA. N-carbamylglutamate in emergency management of hyperammonemia in neonatal acute onset propionic and methylmalonic aciduria. Neonatology. 2010;97(3):286\u201390. https:\/\/doi.org\/10.1159\/000255168.","journal-title":"Neonatology"},{"key":"449_CR34","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1172-3-2","volume":"3","author":"V Levrat","year":"2008","unstructured":"Levrat V, Forest I, Fouilhoux A, Acquaviva C, Vianey-Saban C, Guffon N. Carglumic acid: an additional therapy in the treatment of organic acidurias with hyperammonemia? Orphanet J Rare Dis. 2008;3:2. https:\/\/doi.org\/10.1186\/1750-1172-3-2.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"449_CR35","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1203\/PDR.0b013e318179454b","volume":"64","author":"M Tuchman","year":"2008","unstructured":"Tuchman M, Caldovic L, Daikhin Y, et al. N-carbamylglutamate markedly enhances ureagenesis in N-acetylglutamate deficiency and propionic acidemia as measured by isotopic incorporation and blood biomarkers. Pediatr Res. 2008;64(2):213\u20137. https:\/\/doi.org\/10.1203\/PDR.0b013e318179454b.","journal-title":"Pediatr Res"},{"issue":"4","key":"449_CR36","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s1096-7192(03)00095-7","volume":"79","author":"B Gebhardt","year":"2003","unstructured":"Gebhardt B, Vlaho S, Fischer D, Sewell A, Bohles H. N-carbamylglutamate enhances ammonia detoxification in a patient with decompensated methylmalonic aciduria. Mol Genet Metab. 2003;79(4):303\u20134. https:\/\/doi.org\/10.1016\/s1096-7192(03)00095-7.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"449_CR37","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1159\/000443630","volume":"109","author":"S Yap","year":"2016","unstructured":"Yap S, Leong HY, Abdul Aziz F, et al. N-carbamylglutamate is an effective treatment for acute neonatal hyperammonaemia in a patient with methylmalonic aciduria. Neonatology. 2016;109(4):303\u20137. https:\/\/doi.org\/10.1159\/000443630.","journal-title":"Neonatology"},{"issue":"4","key":"449_CR38","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.clinthera.2010.04.004","volume":"32","author":"E Soyucen","year":"2010","unstructured":"Soyucen E, Demirci E, Aydin A. Outpatient treatment of propionic acidemia-associated hyperammonemia with N-carbamoyl-L-glutamate in an infant. Clin Ther. 2010;32(4):710\u20133. https:\/\/doi.org\/10.1016\/j.clinthera.2010.04.004.","journal-title":"Clin Ther"},{"issue":"4","key":"449_CR39","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ymgme.2013.05.018","volume":"109","author":"M Abacan","year":"2013","unstructured":"Abacan M, Boneh A. Use of carglumic acid in the treatment of hyperammonaemia during metabolic decompensation of patients with propionic acidaemia. Mol Genet Metab. 2013;109(4):397\u2013401.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"449_CR40","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10545-005-5260-7","volume":"28","author":"B Gebhardt","year":"2005","unstructured":"Gebhardt B, Dittrich S, Parbel S, Vlaho S, Matsika O, Bohles H. N-carbamylglutamate protects patients with decompensated propionic aciduria from hyperammonaemia. J Inherit Metab Dis. 2005;28(2):241\u20134. https:\/\/doi.org\/10.1007\/s10545-005-5260-7.","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl. 2","key":"449_CR41","doi-asserted-by":"publisher","first-page":"S219","DOI":"10.1007\/s10545-008-0777-1","volume":"31","author":"S Jones","year":"2008","unstructured":"Jones S, Reed CA, Vijay S, Walter JH, Morris AA. N-carbamylglutamate for neonatal hyperammonaemia in propionic acidaemia. J Inherit Metab Dis. 2008;31(Suppl. 2):S219\u201322. https:\/\/doi.org\/10.1007\/s10545-008-0777-1.","journal-title":"J Inherit Metab Dis"},{"key":"449_CR42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/8904_2011_54","volume":"2","author":"S L\u00e9vesque","year":"2012","unstructured":"L\u00e9vesque S, Lambert M, Karalis A, Melancon S, Russell L, Braverman N. Short-term outcome of propionic aciduria treated at presentation with N-carbamylglutamate: a retrospective review of four patients. JIMD Rep. 2012;2:97\u2013102. https:\/\/doi.org\/10.1007\/8904_2011_54.","journal-title":"JIMD Rep."},{"issue":"1","key":"449_CR43","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00431-009-1036-7","volume":"169","author":"BC Schwahn","year":"2010","unstructured":"Schwahn BC, Pieterse L, Bisset WM, Galloway PG, Robinson PH. Biochemical efficacy of N-carbamylglutamate in neonatal severe hyperammonaemia due to propionic acidaemia. Eur J Pediatr. 2010;169(1):133\u20134. https:\/\/doi.org\/10.1007\/s00431-009-1036-7.","journal-title":"Eur J Pediatr"},{"issue":"3\u20134","key":"449_CR44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3233\/TRD-180031","volume":"3","author":"N Ah Mew","year":"2018","unstructured":"Ah Mew N, Cnaan A, McCarter R, et al. Conducting an investigator-initiated randomized double-blinded intervention trial in acute decompensation of inborn errors of metabolism: lessons from the N-Carbamylglutamate Consortium. Transl Sci Rare Dis. 2018;3(3\u20134):157\u201370. https:\/\/doi.org\/10.3233\/TRD-180031.","journal-title":"Transl Sci Rare Dis."}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00449-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00449-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00449-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T04:02:26Z","timestamp":1713844946000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00449-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["449"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00449-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"assertion":[{"value":"30 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study, medical writing assistance and the open access fee were funded by Recordati Rare Diseases. The funding source was involved in the writing of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sufin Yap has received funding for conferences and honorarium for lectures, master classes, advisory boards and \u2018meet the expert\u2019 sessions from Recordati Rare Diseases; and honorarium for expert advice from OpenVie. Vincenzo Giordano is an employee of Recordati Rare Diseases. Delphine Lamireau, Francois Feillet, Angeles Ruiz Gomez, James Davison, and Trine Tangeraas have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study is being conducted in accordance with the ethical standards of the institutional and\/or national research committees at each centre and with the 1964 Declaration of Helsinki, as revised in 2013. The study protocol has been approved by the local institutional review board at each study site.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent is being collected from all participants or their caregivers before initiating the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets used and\/or analysed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"SY, DL, FF, ARG, JD and TT enrolled patients and contributed to the interpretation of the results, and VG contributed to the study design and interpretation of the results. All authors reviewed and revised the manuscript for important intellectual content, approved the version to be published, and agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}